Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

East Hanover, New Jersey 07936


Purpose:

Many people with type 2 diabetes cannot maintain target blood glucose levels when taking a single oral drug. The purpose of this study is to assess the safety and effectiveness of vildagliptin, an unapproved drug, in lowering overall blood glucose levels when added to pioglitazone in people with type 2 diabetes not at target blood glucose levels on either pioglitazone or rosiglitazone alone.


Criteria:

Inclusion Criteria: - Blood glucose criteria must be met - Previously responded, as defined by the protocol, to treatment with pioglitazone or rosiglitazone - Body mass index (BMI) in the range 22-45 Exclusion Criteria: - Type 1 diabetes - Pregnancy or lactation - Evidence of serious cardiovascular complications - Evidence of serious diabetic complications - Laboratory value abnormalities as defined by the protocol - Known sensitivity to pioglitazone - Other protocol-defined exclusion criteria may apply


NCT ID:

NCT00099853


Primary Contact:

Study Director
Novartis Pharmaceuticals
Novartis Pharmaceuticals


Backup Contact:

N/A


Location Contact:

East Hanover, New Jersey 07936
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: December 16, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.